Fierce Biotech June 25, 2023
Though continuous glucose monitors have long been more widely used among people with Type 1 diabetes, new research has increasingly shown that the Type 2 population can majorly benefit from CGM use, too—so much so that earlier this year, the Centers for Medicare & Medicaid Services in the U.S. expanded CGM coverage to include more Type 2 users.
Doubling down on its own push to bring its CGM technology to more people with Type 2 diabetes is Abbott, which unveiled a new partnership with the American Diabetes Association (ADA) and kicked off its previously announced WeightWatchers collaboration during the ADA’s annual scientific sessions in San Diego on Saturday.
The WeightWatchers team-up allows people who have been prescribed one...
Today's Sponsors
Today's Sponsor